How it works
How Much Does Radiotherapy for uterine cancer Cost in China?
Radiotherapy for uterine cancer in China typically costs from $6,500 to $13,500. The final price depends on the chosen technology, hospital tier, and city location. In the US, similar procedures cost around $31,000 on average. China offers savings of around 68%. Standard packages often include free airport transfers, professional medical interpreters, and initial consultations.
- IMRT sessions: Costs are 20-30% higher than standard radiation due to precision targeting.
- Brachytherapy: Internal radiation typically costs less than external beam sessions but requires specialized equipment.
- Advanced LINAC: Technologies like TrueBeam add a premium for reduced treatment times and accuracy.
- Destination hubs: Costs in Guangzhou and Chengdu are often 15-20% lower than in Shanghai.
Bookimed Expert Insight: Choosing specialized oncology centers in Guangzhou provides access to world-class expertise at a fraction of Western costs. Fuda Cancer Hospital offers JCI-accredited care and maintains a formal cooperation with the US-based MD Anderson Cancer Center. Patients benefit from advanced options like NanoKnife and cryosurgery, which are often integrated into multimodal treatment plans. Clinics here typically respond to international inquiries within 24 hours, ensuring rapid commencement of vital cancer therapy.
| China | Turkey | Austria | |
|---|---|---|---|
| Radiotherapy for uterine cancer | ≈ $6,500 | from $6,000 | from $6,600 |
Discover the Best Radiotherapy for uterine cancer Clinics in China: 2 Verified Options and Prices
Jinshazhou Hospital of Guangzhou University of Chinese Medicine

Radiotherapy for uterine cancer Overview in China
- Radiotherapy - from $8,000This therapy uses high-energy waves to destroy cancer cells, providing a non-surgical treatment with few side effects.
- Stereotaxic radiosurgery - from $10,800This therapy targets tumors with precise radiation, avoiding damage to surrounding tissues.
- Radiation therapy for brain tumor - from $6,700This therapy aims to destroy brain tumors using high-energy rays, reducing symptoms and improving survival rates.
- Radiotherapy for prostate cancer - from $10,000This therapy targets prostate tumors with radiation, annihilating cancer cells while preserving healthy tissue.
- Radiotherapy for lung cancer - from $7,000This therapy aims to kill cancer cells in the lungs using high-energy x-rays.
Day 1
- Arrive at the medical facility.
- Consult with oncologist and radiologist.
- Undergo medical tests including blood tests and imaging scans.
Day 2
- Receive results from medical tests.
- Discuss treatment plan with specialists.
- Understand the process of Radiotherapy.
Day 3 - Day 5
- Start the Radiotherapy sessions.
- Each session lasts for 1-2 hours without anesthesia.
- Experience minor discomfort during the treatment.
- Sessions are usually daily, excluding weekends.
Day 6
- Rest day, no Radiotherapy sessions.
- Monitor any side effects and report to the medical team.
Week 2 - Week 6
- Continuation of daily Radiotherapy sessions.
- Regular monitoring of side effects.
- Adjustments to treatment plan if needed.
Week 7
- End of Radiotherapy sessions.
- Post-treatment consultation with specialists.
- Plan for follow-up appointments.
Week 8 - Week 10
- Period of recovery and rest at home.
- Gradual return to daily activities.
- Regular follow-up appointments for monitoring.
Week 11
- Return to work, depending on individual recovery.
- Continue follow-up appointments.
- See the final result of the treatment.
Please note that each patient"s case is unique, and timelines may vary based on individual health conditions and response to treatment.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

He Weibing
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova





